FDA Novel Drugs
Generic Name: navepegritide
- Brand Name: Yuviwel
- Drug Class: CNP analog prodrug
- Sponsor by: Ascendis Pharma Growth Disorders A/S
- Approval Date: 27/02/2026
Overview Yuviwel (navepegritide) is a once‑weekly, subcutaneous C‑type natriuretic peptide (CNP) analog approved by the U.S. Food and Drug Administration in February 2026 to increase linear growth in pediatric patients
Author: Darshan Singh
Generic Name: pegzilarginase‑nbln
- Brand Name: Loargys
- Drug Class: Enzyme replacement therapy
- Sponsor by: Immedica Pharma AB / Immedica Pharma US Inc.
- Approval Date: 23/02/2026
Loargys (pegzilarginase‑nbln) is a pegylated, cobalt‑substituted recombinant human arginase‑1 enzyme granted accelerated FDA approval on 23 February 2026 for treatment of hyperargininemia in adults and children 2 years and older
Author: Darshan Singh
Generic Name: milsaperidone
- Brand Name: BYSANTI
- Drug Class: Small molecule
- Sponsor by: Vanda Pharmaceuticals
- Approval Date: 20/02/2026
The formal approval of Bysanti (milsaperidone) by the United States Food and Drug Administration (FDA) on February 20, 2026, signifies a sophisticated regulatory and pharmacological evolution within the atypical antipsychotic
Author: Darshan Singh
Generic Name: Difamilast
- Brand Name: Adquey
- Drug Class: Small molecule
- Sponsor by: Otsuka Pharmaceutical
- Approval Date: 12/02/2026
On February 12, 2026, the U.S. Food and Drug Administration (FDA) approved the New Drug Application (NDA) for ADQUEY™ (difamilast 1%) ointment for the topical treatment of mild-to-moderate atopic dermatitis
Author: Darshan Singh
Generic Name: copper histidinate
- Brand Name: ZYCUBO
- Drug Class: Gene
- Sponsor by: Sentynl Therapeutics
- Approval Date: 12/01/2026
On January 12, 2026, the U.S. Food and Drug Administration (FDA) officially approved ZYCUBO® (copper histidinate) for injection, marking a historic achievement as the first and only approved treatment for
Author: Darshan Singh
Generic Name: tradipitant
- Brand Name: NEREUS™.
- Drug Class: Others
- Sponsor by: Vanda Pharmaceuticals Inc.
- Approval Date: 30/12/2025
On December 30, 2025, the U.S. Food and Drug Administration (FDA) approved Nereus (tradipitant), an oral neurokinin-1 (NK-1) receptor antagonist, for the prevention of vomiting induced by motion in adults[1].
Author: Darshan Singh
Generic Name: narsoplimab-wuug
- Brand Name: YARTEMLEA
- Drug Class: MASP-2
- Sponsor by: Omeros Corporation
- Approval Date: 23/12/2025
On December 23, 2025, the U.S. Food and Drug Administration (FDA) approved Yartemlea (narsoplimab-wuug), a novel MASP-2 inhibitor developed by Omeros Corporation. This marks a significant regulatory milestone as Yartemlea